HUMA

1.10

4.76% 0.05

Handel nachbörslich: 1.10

Humacyte Inc (HUMA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HUMA? Forum Prognose

Schlusskurs vom Vortag:

$1.05

Offen:

$1.025

24-Stunden-Volumen:

6.84M

Relative Volume:

1.00

Marktkapitalisierung:

$243.11M

Einnahmen:

$2.04M

Nettoeinkommen (Verlust:

$-43.21M

KGV:

-5.3217

EPS:

-0.2067

Netto-Cashflow:

$-105.93M

1W Leistung:

+33.28%

1M Leistung:

+57.14%

6M Leistung:

-17.29%

1J Leistung:

-56.52%

1-Tages-Spanne:

$1.02

$1.12

1-Wochen-Bereich:

$0.8253

$1.12

52-Wochen-Spanne:

$0.5469

$2.93

Humacyte Inc Stock (HUMA) Company Profile

Firmenname

Humacyte Inc

Sektor

Healthcare (1113)

Branche

Biotechnology (618)

Telefon

919-313-9633

Adresse

2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM

Mitarbeiter

184

Twitter

Nächster Verdiensttermin

2026-05-13

Neueste SEC-Einreichungen

HUMA's Discussions on Twitter

Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HUMA Humacyte Inc	1.095	233.12M	2.04M	-43.21M	-105.93M	-0.2067
VRTX Vertex Pharmaceuticals Inc	435.92	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.42	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.61	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-27	Eingeleitet	Barclays	Overweight
2025-05-14	Fortgesetzt	H.C. Wainwright	Buy
2024-12-20	Bestätigt	H.C. Wainwright	Buy
2023-12-11	Eingeleitet	H.C. Wainwright	Buy
2023-08-14	Hochstufung	Piper Sandler	Underweight → Neutral
2023-06-22	Eingeleitet	Cantor Fitzgerald	Overweight
2022-05-16	Herabstufung	Piper Sandler	Overweight → Underweight
2021-10-29	Eingeleitet	Cowen	Outperform
2021-09-24	Eingeleitet	Oppenheimer	Outperform
2021-09-22	Eingeleitet	BTIG Research	Buy
2021-09-16	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Humacyte Inc Aktie (HUMA) Neueste Nachrichten

01:00 AM

HUMA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus

01:00 AM

09:05 AM

Humacyte presents dialysis access vessel research at VASA meeting - Investing.com

09:05 AM

08:22 AM

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access - The Manila Times

08:22 AM

08:00 AM

Dialysis graft that self-repairs despite hundreds of needle sticks - Stock Titan

08:00 AM

May 22, 2026

HUMA Technical Analysis | Trend, Signals & Chart Patterns | HUMACYTE INC (NASDAQ:HUMA) - ChartMill

May 22, 2026

May 21, 2026

Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today? - MSN

May 21, 2026

May 20, 2026

Humacyte (HUMA) director Kathleen Sebelius purchases 56,818 shares at $0.88 - Stock Titan

May 20, 2026

Humacyte (HUMA) director adds 11,000 shares at about $0.89 - Stock Titan

May 20, 2026

Humacyte (HUMA) CFO executes 45,887-share sell-to-cover trade for RSU taxes - Stock Titan

May 20, 2026

Humacyte (HUMA) CMO executes 45,887-share tax sell-to-cover under 10b5-1 plan - Stock Titan

May 20, 2026

Humacyte’s Symvess added to VA hospital contract system - Investing.com UK

May 20, 2026

Humacyte’s Symvess added to VA hospital contract system By Investing.com - Investing.com South Africa

May 20, 2026

VA hospitals to get easier access to Humacyte Symvess product - Stock Titan

May 20, 2026

May 19, 2026

Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization - Insider Monkey

May 19, 2026

May 18, 2026

Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail

May 15, 2026